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Commentary
Few current or past risk assessment issues are 
as challenging as those raised by bisphenol A 
(BPA). There is widespread BPA exposure to 
the general public, including pregnant women 
and infants, and the chemical is in the class of 
environmental hormones for which risk assess-
ment approaches are still developing. Given 
that BPA is one of a large number of estrogenic 
chemicals to which humans are frequently 
exposed, this chemical represents something 
of a test case. Increasing the stakes is evidence 
for low-dose effects within the range of human 
exposure for end points that have implications 
for reproductive health and cancer. However, 
this evidence is in dispute, with major scien-
tific and regulatory bodies disagreeing over 
BPA’s low-dose risks. Health Canada (2008) 
calls it a hazardous substance and has banned it 
from baby bottles. In contrast, the U.S. Food 
and Drug Administration and the European 
Food Safety Authority (EFSA) have found no 
immediate cause for concern and are not tak-
ing action to limit exposure.
Other recent reviews and commentaries 
have focused on the evidence of harm from 
low-dose exposure (Bucher 2009; Myers et al. 
2009; Tyl 2008); we do not address those data 
here. Rather, we focus on an element that has 
not received critical attention: the claim raised 
by the EFSA that rapid metabolic clearance 
of BPA via first-pass glucuronide metabo-
lism minimizes internal exposure to free BPA 
(EFSA 2008). We find this argument to be 
simplistic, ignoring several lines of evidence 
that internal BPA exposure can be substantial 
in humans despite rapid conjugation.
The Rapid Metabolism 
Argument
The EFSA (2008) pointed to pharmacokinetic 
data in humans showing rapid BPA metabo-
lism to the glucuronide conjugate as reason to 
decrease emphasis on the low-dose effects seen 
in rodents. Because only the parent compound 
binds to the estrogen receptor, conjugation is 
a detoxification mechanism that represents the 
major clearance pathway for BPA. Two studies 
evaluated the metabolic fate of BPA in small 
numbers of human volunteers ingesting low 
doses of deuterated BPA (d-BPA), with the 
labeled chemical used to increase sensitivity 
and distinguish administered BPA from back-
ground sources (e.g., dietary, contamination 
from plastics in labware) (Völkel et al. 2002, 
2008). These studies failed to find detectable 
concentrations of free d-BPA in human plasma 
or urine [limit of detection (LOD) = 2.3 µg/L 
in plasma; see Table 1]. The kinetic profile for 
the conjugated metabolite (d-BPA glucuronide) 
showed a rapid peak followed by urinary 
elimination with a terminal half-life of 5.3 hr 
(Völkel et al. 2002). These studies have been 
interpreted as indicating more rapid and com-
plete metabolic clearance of BPA in humans 
relative to the rat, in which circulating parent 
compound can be detected and the clearance 
of BPA glucuronide is slower (t1/2 of 20–80 hr) 
(EFSA 2008; Völkel et al. 2002, 2008). This 
was attributed to different elimination pathways 
in rats versus humans, given that the molecu-
lar size cutoff for urinary excretion is larger in 
humans (550 Da) compared with that in rats 
(350 Da). This results in elimination of conju-
gated BPA (404 Da) by biliary/fecal elimina-
tion in the rat but via urine in humans (Völkel 
et al. 2002). This would preclude entero  hepatic 
recirculation in humans, in contrast to rats, in 
which intestinal β-glucuronidases could break 
down excreted conjugate and liberate BPA for 
systemic reabsorption. This rationale has been 
used to argue the irrelevance of rat data showing 
effects at low doses, the hypothesis being that at 
low doses in humans, extensive glucuronidation 
can essentially prevent fetal exposure to BPA.
With respect to neonatal exposure, the 
EFSA (2008) recognized that the human data 
are from adult volunteers and would not neces-
sarily apply to neonates, who might ingest BPA 
via breast milk or formula. They concluded that 
early-life immaturity in glucuronidation capac-
ity is likely to be augmented by sulfo  transferases 
given that BPA is a substrate for sulfation, and 
there is earlier ontogeny of sulfo  transferases 
compared with UDP-glucuronosyltransferases. 
This was demonstrated for the therapeutic drug 
acetaminophen, which undergoes a shift in 
metabolic clearance from primarily sulfation 
to primarily glucuronidation with increasing 
postnatal age (Allegaert et al. 2005; Levy et al. 
1975; Miller et al. 1976). Therefore, the EFSA 
(2008) concluded that between sulfation and 
glucuronidation, sufficient BPA conjugation 
capacity exists in neonates to prevent exposure 
to the parent compound. 
Based on these arguments, the EFSA 
maintains the tolerable daily intake (TDI) of 
BPA for the European Union at 0.05 mg/
kg/day (EFSA 2008), an exposure rate that 
is 200 times greater than that associated 
with adverse effects in some rodent studies 
(Vandenberg et al. 2007).
Why Rapid Metabolism  
Is Not the End of the Story
Although cross-species pharmacokinetic dif-
ferences exist, there is still ample opportunity 
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for human exposure to free BPA. That is 
because β-glucuronidases exist not only in 
the intestines but also throughout the body, 
including the placenta and fetal liver. This 
creates the potential for local activation of 
the conjugated form back to free BPA in 
numerous tissues. This is analogous to the 
situation for endogenous estrogens, which are 
transported as sulfate conjugates and can be 
cleaved to active hormone by tissue sulfatases 
(Iwamori 2005). β-Glucuronidase activity is 
widely distributed throughout mammalian 
tissues and is present in both the endo  plasmic 
reticulum and lysosomes (Paigen 1989; 
Sperker et al. 1997). Although its primary 
physiologic role is the degradation of proteo-
glycans, the enzyme is also able to deconjugate 
a variety of xeno  biotic substrates that have 
already undergone phase II glucuronidation. 
This can result in conjugation–deconjugation 
cycling that does not involve entero  hepatic 
recirculation, as documented for the drug 
diflunisal. Treatment of rats with a specific 
β-glucuronidase inhibitor decreased metabolic 
clearance of diflunisal by 54% in experiments 
in which the bile duct was cannulated to pre-
vent entero  hepatic recirculation (Brunelle and 
Verbeeck 1997). Deconjugation of a vari-
ety of other xeno  biotic metabolites has been 
documented in human liver preparations, 
including acetaminophen (Bohnenstengel 
et al. 1999) and the aromatic amines ben-
zidine and 4-aminobiphenyl (Zenser et al. 
1999). β-Glucuronidase protein levels and 
enzyme activity were readily detectable and 
varied widely in human liver and kidney sam-
ples taken from 30 and 18 individuals, respec-
tively (Sperker et al. 1997).
Additional evidence also argues against 
a simplistic approach. A reanalysis of the 
National Health and Nutrition Examination 
Survey (NHANES) BPA urinary biomonitor-
ing results from 1,469 adult partici  pants sug-
gested a longer than expected half-life of BPA 
(Stahlhut et al. 2009) based on modeling of 
the fasting time (before sample draw) rela-
tive to urinary concentration and the assump-
tion that most BPA exposure comes from the 
diet. The stable level of urinary BPA may have 
been due to non  dietary BPA exposures, tis-
sue accumulation and storage of free BPA, 
and/or conjugation–deconjugation cycling of 
BPA involving β-glucuronidase. It is note-
worthy that whereas the terminal half-life is 
reported to be only 5.3 hr in humans after 
d-BPA administration (Völkel et al. 2002), 
the time course shows no additional d-BPA 
Table 1. Studies evaluating free BPA in biological fluids.
Study Exposure Analytical method Results Comments
Domoradzki et al. 2003  Pregnant rats 
gavaged with 14C 
BPA, 10 mg/kg, on 
GD11, GD13, or GD16 
Radiochemical HPLC: 
LOD ~ 35 µg/L; tests run to 
ensure that procedures did 
not cleave BPA glucuronide 
to BPA
Free BPA not detected in many 
samples early in gestation; GD16 
free BPA detectable in all tissues: 
placenta > maternal plasma 
> fetus; ratio of free/conjugated: 
fetus > placenta > maternal plasma
Although fetus had 3.6-fold less free BPA than 
maternal plasma, free/conjugated BPA ratio 
was much greater in fetus; may reflect altered 
conjugation/deconjugation balance in fetal 
compartment; data from early period before 
enterohepatic circulation created a secondary Cmax 
Ikezuki et al. 2002 Humans (mother/
fetus) background 
exposure (n = 32–38)
ELISA: details not given, 
but accuracy checked 
against standard HPLC 
method
Free BPA detected in maternal 
serum, ovarian follicular fluid, 
and cord blood at similar levels; 
amniotic fluid was 5 times higher 
in early but not late pregnancy
Higher free BPA in amniotic fluid early 
in pregnancy may be related to changing 
composition: coming from maternal plasma early 
vs. fetal urine late in gestation; free BPA is in 
maternal plasma but unlikely in urine 
Schönfelder et al. 2002 Humans (mother/
fetus) background 
exposure (n = 37)
GC-MS: LOD = 0.01 µg/L 
LOQ = 0.1 µg/L
Free BPA detected in placenta 
> maternal plasma > fetal plasma; 
fetal > maternal in 14 of 37 
samples, with male fetus > female 
fetus in these cases
Methods avoided BPA leaching from labware 
into sample; differences across tissues and sexes 
suggest free BPA is biologically based rather than 
from background contamination
Takahashi and Oishi 2000 Pregnant rats dosed 
on GD18 with 1 g/kg 
gavage
HPLC: LOD = 5 µg/L Free BPA detected in maternal 
tissues > fetal tissue ≥ maternal 
blood; fetal t1/2 3 times greater 
than maternal t1/2 
High-dose rat study has limited relevance, but it 
demonstrates distribution to fetal compartment; 
enterohepatic recirculation likely affects t1/2 in 
both fetus and mother but does not explain longer 
t1/2 in fetus
Takeuchi et al. 2004 Rats background 
exposure (n = 10/sex)
HPLC: details not clear but 
appear to involve standard 
solvent extraction
Free BPA detected in males 
> females
Sex differential corresponds to lower BPA 
conjugating capacity in male liver microsomes and 
lower expression of UGT2B1 
Takeuchi and Tsutsumi 2002  Humans: background 
exposure (n = 11 
men, 14 women)
ELISA: accuracy checked 
against HPLC method
Free BPA detected in males 
> females
Free BPA correlated with serum testosterone in 
both men and women, suggesting androgen effect 
on BPA fate 
Tan and Mohd 2003 Humans: background 
exposure (n = 180 
females)
GC-MS: LOD = 0.05 µg/L Free BPA detected in cord blood in 
88% of samples
Demonstrated potential utility of biomonitoring 
free BPA and other alkylphenols in cord blood
Völkel et al. 2002 Humans: dosed orally 
with 5 mg d-BPA 
(n = 4)
LC-MS: LODplasma = 2.3 µg/L; 
LODurine = 1.4 µg/L
No detection of free BPA even 
though d-BPA glucuronide was 
high (160 µg/L blood); d-BPA 
glucuronide, t1/2 = 5.3 hr
Lack of free BPA attributed to “practically 
complete” first-pass metabolism and lack of 
enterohepatic circulation; detection of free BPA 
in background samples attributed to plastic 
contamination 
Völkel et al. 2008 Humans: background 
exposure (n = 287)
LC-MS: LODurine = 0.3 µg/L; 
LOQurine = 1.25–5 µg/L 
10% of urine samples with low 
detection (> LOD, < LOQ)
Free BPA in urine attributed to contamination 
from house dust or plastics because BPA was also 
found in blanks; d-BPA dosing did not find free BPA 
in urine
Völkel et al. 2008 Human: dosed orally 
with 5 mg d-BPA 
(n = 1)
HPLC-MS: LODurine for 
d-BPA was not stated
Free d-BPA not detected in any 
urine samples from this subject
Results used to assert that if free BPA is detected 
in urine, it is from contaminants and not free BPA
Yamada et al. 2002 Humans: background 
exposure (n = 200 
women)
ELISA: LOD = 0.2 µg/L; 
method previously 
validated against HPLC 
method
Second trimester serum samples in 
Japanese women showed steady 
decline in free BPA from 1989 to 
1998
No clear explanation of decreasing BPA in serum, 
but results were significant (p < 0.001); free BPA 
lower in amniotic fluid than maternal serum
Abbreviations: Cmax, maximum concentration; ELISA, enzyme-linked immunosorbent assay; GC, gas chromatography; GD, gestation day; HPLC, high-performance liquid chromatogra-
phy; LC, liquid chromatography; LOQ, limit of quantification; MS, mass spectrometry. BPA metabolism and human risk
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glucuronide removal beyond 20 hr (addi-
tional data from Völkel et al. 2002 presented 
in Teeguarden et al. 2005). This is consistent 
with delayed excretion due to long-term tissue 
storage and/or conjugation–deconjugation 
cycling. The terminal half-life in cynomol-
gus monkeys dosed orally with 14C-BPA was 
9.7 hr (Kurebayashi et al. 2002). Thus, the 
cross-species difference in terminal half-life of 
BPA glucuronide may not be as large as stated 
(EFSA 2008). Finally, there are uncertain-
ties when comparing half-life across studies 
involving administered oral doses that were 
100–1,000 times higher in the rat study 
(Domoradzki et al. 2003; Pottenger et al. 
2000) than in the human study (Völkel et al. 
2002). Although glucuroni  da  tion is consid-
ered a high-capacity pathway, one cannot rule 
out the possibility that the rat to human dif-
ference in half-life was affected by the differ-
ence in administered dose.
Developmental studies suggest rapid 
ontogeny of β-glucuronidase, because it is 
detected prenatally in liver, kidney, and lung 
in a variety of laboratory species, with activ-
ity particularly high in placenta (Lucier et al. 
1977). Human placenta also has considerable 
β-glucuronidase activity, and this enzyme is 
critical for proper in utero develop  ment (Collier 
et al. 2009; Paigen 1989; Sperker et al. 1997). 
An inherited deficiency leads to hydrops fetalis, 
a birth defect related to improper fetal break-
down of muco  poly  saccharides and water accu-
mulation. Because glucuroni  dation capacity is 
immature in early life, the net balance tends to 
be toward deconjugation in the animal mod-
els and tissues studied (Lucier et al. 1977). 
This makes BPA deconjugation a potentially 
important pharmaco  kinetic factor during the 
  peri  natal period.
Thus, it is apparent that one has to con-
sider the potential for β-glucuronidase–
mediated deconjugation of BPA glucuronide 
in placental and fetal tissues. Even though 
glucuronidation may be rapid, the reported 
terminal half-life of circulating BPA 
glucuronide, 5.3 hr, affords ample opportunity 
for transport to placenta and deconjugation 
back to BPA. This and the fact that the fetus 
itself contains β-glucuronidase increase the 
chances for substantive fetal exposure to free 
BPA. By focusing on rapid conjugation and 
not considering sites of deconjugation other 
than the intestine (entero  hepatic recircula-
tion), the EFSA has not considered the impli-
cations of BPA glucuronide deconjugation in 
placental and fetal tissues. This issue may be 
a key determinant of cross-species extrapola-
tion of BPA internal dose, but it has yet to 
be addressed in BPA pharmacokinetic models 
(Edginton and Ritter 2009; Teeguarden et al. 
2005) or regulatory determinations.
What Is the Meaning of Free 
BPA Detection in Human 
Samples?
The Völkel et al. (2002, 2008) human dos-
ing studies failed to detect free BPA (Table 1) 
and so were interpreted by the EFSA (2008) 
as supportive of rapid metabolic clearance 
and negligible exposure in adults as well as 
the fetus. However, numerous other studies 
have detected free BPA in both humans and 
rats, either associated with general background 
exposure or in experiments where rodents 
were dosed with BPA (Table 1). Free BPA 
was detected by a variety of methods and was 
found not only in adult blood but also in pla-
cental and fetal samples. Dekant and Volkel 
(2008) argued that the detection of free BPA 
in such studies may result from background 
contamination from labware and indoor dust. 
Further, some free BPA may be formed by 
cleavage from the glucuronide present in the 
sample when readying the sample for analysis 
(Dekant and Volkel 2008). However, many of 
the cited studies were aware of these potential 
artifacts and took steps to prevent false-positive 
detection of free BPA. Further, our review of 
the free BPA data derived from these stud-
ies suggests that this result is not artifactual. 
Quite the contrary, these data suggest patterns 
of occurrence that have important implications 
for BPA risk assessment.
Figure 1 includes studies in which free BPA 
was detected in rats dosed during pregnancy, 
demonstrating maternal serum BPA greater 
than fetal BPA in two studies (Domoradski 
et al. 2003; Takahashi and Oishi 2000). 
In a study in which placental BPA was also 
measured, the placenta had a higher BPA 
concentration than did the maternal or fetal 
compartments. This is consistent with human 
free BPA data collected in a biomonitoring 
study of pregnant women exposed to back-
ground sources of BPA (Schönfelder et al. 
2002). Once again, placenta had the highest 
concentration, followed by maternal and fetal 
compartments (Figure 2). These trends have a 
plausible biological basis in that placenta has 
extensive β-glucuronidase activity (see above) 
and so may be an important site of metabolite 
deconjugation and resultant fetal exposure. 
Although peak fetal concentrations of free BPA 
were less than maternal concentrations in both 
rats and humans, a more detailed time course 
in rats indicated that cumulative free BPA 
exposure was actually greatest in the fetus [fetal 
area under the curve was 73% greater than 
maternal (Takahashi and Oishi 2000)]. This 
may reflect ongoing deconjugation in placenta 
and fetus that prevents free BPA from declin-
ing as rapidly as in the maternal system. Also 
of note in this study was the finding of much 
higher concentrations of free BPA in liver and 
kidney compared with blood, again suggesting 
the importance of local tissue deconjugation 
and/or binding in determining free BPA dose. 
In this study, Takahashi and Oishi (2000) 
used a very large dose (1 g/kg), so their results, 
although consistent with the others cited, 
should be repeated at more relevant doses.
Additional evidence of BPA deconjugation 
during gestation comes from rat data showing 
that the ratio of glucuronide to free BPA var-
ies across maternal, placental, and fetal com-
partments (Figure 1). Although Domoradzki 
et al. (2003) reported no selective tissue affin-
ity for BPA or its metabolite, their data show 
a continuous decrease in glucuronide to free 
Figure 1. Free BPA and ratio of conjugate to free BPA in rats from background exposure or after BPA dosing. 
aData from Takeuchi et al. (2004). bData from Domoradzki et al. (2003). cData from Takahashi and Oishi (2000).
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BPA ratio across these compartments, sug-
gesting a greater role for deconjugation in the 
placenta and fetus than in maternal blood.
The biological plausibility of the free BPA 
data is also supported by the difference between 
sexes in both rats and humans (Figures 1 
and 2). Male rats exhibited greater free BPA 
than did females, consistent with decreased 
expression of the main BPA-glucuronidating 
enzyme [UDP-glucuronosyltransferase 2B1 
(UGT2B1)] in male rat liver (Takeuchi et al. 
2004). The fact that this was also seen in 
humans (Figure 2) suggests that BPA meta-
bolic fate is under hormonal control in both 
species. The sex differential appears to exist 
very early in human development, because free 
BPA was greater in male than female fetuses 
of women receiving BPA exposure from back-
ground sources (Schönfelder et al. 2002).
The risk implications of free BPA detec-
tions need to be explored based upon dose–
response assessment and suitable physiologically 
based pharmacokinetic (PBPK) modeling that 
can relate internal dose of free BPA to adverse 
effect. The existing PBPK models (Edginton 
and Ritter 2009; Teeguarden et al. 2005) have 
not considered the influence of local deconju-
gation reactions. In the only attempt to simu-
late free BPA concentrations, Teeguarden et al.   
(2005) were not able to reproduce the free 
BPA results for rat plasma at the later time 
points (4 and 8 hr after dosing) even though 
their model included entero  hepatic recircula-
tion and plasma protein binding. There is a 
clear need to improve modeling efforts with 
respect to free BPA in maternal, fetal, and 
neonatal tissues across species, with metabo-
lite deconjugation a potentially important ele-
ment. Better calibration of the models against 
the database of free BPA detection (Table 1) 
should be part of this effort. This may be 
facilitated by in vitro studies that evaluate the   
conjugation–deconjugation activity of pla-
centa and other human and rodent tissues. 
Such in vitro data along with additional 
human volunteer studies evaluating BPA con-
centration after controlled exposures (e.g., 
Carwile et al. 2009) will inform the degree of 
variability in human BPA pharmaco  kinetics. 
This is particularly uncertain given the small 
numbers of adult subjects that were involved 
in the detailed pharmaco  kinetic studies 
thus far reported (Völkel et al. 2002, 2008; 
Table 1). A PBPK model parameterized with 
empirical conjugation and deconjugation 
rate constants and calibrated for free BPA is 
needed to relate the dose response for toxic 
effects found in rodents to humans.
What about BPA in Neonates?
The EFSA also considers dietary BPA expo-
sures in neonates to be insignificant because 
of rapid metabolism, in this case not because 
of glucuronidation but because of sulfation. 
Based on analogy with aceta  mino  phen, BPA 
may be conjugated with sulfate rather than 
glucuronide in neonates because of the earlier 
development of sulfo  transferases. However, 
sulfation does not end the biological activity 
of endogenous hormones, so there is no rea-
son to believe it will do so for sulfated BPA. 
Sulfated estrogens, mainly in the form of 
estrone sulfate, have a long half-life in blood, 
where their concentration is much higher than 
the active hormone (Nakamura et al. 2005). 
These conjugates act as a circulating reservoir 
of inactive hormone that can be deconjugated 
in local tissues by aryl  sulfatase C, a widely 
expressed micro  somal enzyme that is espe-
cially prevalent in estrogen-responsive tissues 
(Reed et al. 2005; Tobacman et al. 2002). 
Given that sulfo  transferases also exist in these 
tissues, the balance between conjugation and 
deconjugation at a particular life stage and in 
a specific tissue is a key determinant of local 
estrogen dose. This has not been studied for 
BPA and is a critical data need for develop-
ing improved PBPK models for the postnatal 
period. However, it is reasonable to assume 
that the BPA sulfate conjugate would be sub-
ject to deconjugation in a manner similar to 
endogenous sulfated estrogens. This is perti-
nent to the postnatal period as aryl  sulfatase C 
activity develops in utero and is readily detect-
able in human neo  natal liver (Richard et al. 
2001). Thus, sulfation of BPA in neonates 
does not guarantee negligible internal dose as 
assumed by the EFSA.
Another consideration is that this argu-
ment is based on analogy with acetamino-
phen. However, it is uncertain whether the 
sulfo  transferases present in neonates will be 
as efficient in conjugating BPA as they are for 
acetaminophen. This represents another key 
data gap. Finally, genetic polymorphism in 
major sulfotransferases such as SULT1A1*2 
can decrease conjugating activity 2- to 10-fold 
(Hildebrandt et al. 2007; Nagar et al. 2006; 
Ohtake et al. 2006). This can be an important 
source of inter  individual variability in neo-
natal BPA conjugation that is not considered 
in the EFSA assessment.
Summary
Free BPA concentrations have been detected 
in a wide range of both human and rodent 
studies and likely reflect the in vivo condition 
rather than artifact. This provides evidence of 
exposure to free BPA in human adults and 
fetuses despite rapid first-pass glucuronidation. 
Deconjugation at local tissue sites by the action 
of β-glucuronidase and aryl  sulfatase C provides 
a plausible mechanism. The EFSA’s review of 
the pharmaco  kinetic evidence concludes that 
cross-species differences in BPA glucuronide 
fate (enterohepatic recirculation in rats; urinary 
excretion in humans) makes low-dose studies in 
rodents less relevant for human risk assessment 
(EFSA 2008). The EFSA also believes that on 
the basis of rapid BPA metabolism and excre-
tion in humans, fetal and neo  natal exposure 
is negligible. However, detection of free BPA 
in human and rodent placenta and fetus is 
contrary to that opinion and argues for plac-
ing importance on deconjugation reactions in 
future risk assessments.
The EFSA TDI of 0.05 mg/kg/day (EFSA 
2008) is orders of magnitude greater than the 
dose found to produce effects in some rodent 
studies. Pharmacokinetic differences across 
species would have to be enormous to justify 
acceptance of a TDI that far above possible 
effect levels. The points raised above demon-
strate the uncertainty in the pharmacokinetic 
argument for maintaining the current EFSA 
TDI. Efforts should be placed on decipher-
ing the dose–response relationship in rodent 
studies and applying it to human risk assess-
ment based upon PBPK models that account 
for metabolite deconjugation in conjunction 
with other pharmacokinetic factors. Such 
PBPK models do not currently exist, and the 
existing models (Edginton and Ritter 2009; 
Teeguarden et al. 2005) cannot fully simulate 
the human and rodent data. Therefore, as an 
interim measure, one may choose to directly 
apply the rodent dose–response relationship 
to humans and seek additional mechanistic 
or epidemiologic data to refine the human 
risk assessment.
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